StemCell Therapy

NEW YORK, Oct. 5, 2022 /PRNewswire/ -- The Global Pregabalin Market by Application and Geography Forecast and Analysis 2022-2026 size is expected to grow by USD 153.03 million from 2022 to 2026, at a CAGR of 3.74%. The increasing presence of a large patient pool related to neuropathic pain, the increasing geriatric population, and the rising applications of pregabalin in various diseases are themajor factors propelling the market growth. However, the growing preference for alternatives and stringent regulatory policies may impede market growth. To get more insights on drivers and challenges Request a Sample PDF

Technavio has announced its latest market research report titled Global Pregabalin Market 2022-2026

Key Market Dynamics:

Market Driver: The presence of a large patient pool related to neuropathic pain is one of the key drivers supporting thepregabalin market growth.Neuropathic pain is associated with various disorders such as diabetic neuropathy, chemotherapy-induced pain, shingles, and herniated disk. There have been growing cases of these disorders, especially in the geriatric population. Meanwhile, the increasing number of individuals preferring chemotherapy for cancer treatment is fueling cases of chemotherapy-induced pain. Furthermore, according to the CDC, the incidence of shingles is approximately four per 1,000 US population annually. Overall, there are an estimated one million cases of herpes zoster in the US annually. Such a scenario will lead to an increase in the adoption of pregabalin, which, in turn, will drive the growth of the market during the forecast period.

Market Challenges: Growing preference for alternatives is one of the key factors hindering thepregabalin market growth.As the current treatments are associated with many unmet needs, end-users are looking to shift to alternative therapies. For instance, diabetic neuropathic pain can be reduced by supplementing essential acids, alpha-lipoic acid, gamma-linolenic acid, and omega-3 fatty acids. Similarly, acupuncture can be an effective way to manage peripheral neuropathy. Acupuncture uses pressure points across the body to realign the body's energy.Thus, the use of these alternative therapies may hinder growth prospects in the forecast period.

To get insights about additional key drivers, trends, and challenges available with Technavio.Read our Sample Report right now!

Market Segmentation

North Americawill be the leading region with 36% of the market's growth during the forecast period. The US and Canada are the key countries for the pregabalin market inNorth America. The increase in the older population, coupled with the established adoption of LYRICA and Cymbalta in new indications and the introduction of new drugs for the treatment of neuropathic pain, will facilitate thepregabalin market growth in North America over the forecast period.

The Neuropathic pain application segment will contribute the highest market share growth during the forecast period. Neuropathic pain affects 20% to 30% of diabetic neuropathy patients. Thus, the demand for pregabalin is rising due to more occurrences of diabetic neuropathy, which is boosting the growth of the market.Pregabalin is an alternative treatment for people with neuropathic pain that has not responded to other drugs.It effectively reduces the symptoms of numerous neuropathic pain conditions and positions itself as a first-line therapy option with exceptional safety and efficacy.These factors will drive segment growth during the forecast period.

View our sample reportfor additional insights into the contribution of all the segments, and regional opportunities in the report.

Some Companies Mentioned with their Offerings

Related Reports:

Pharmaceuticals Wholesale and Distribution Market by Types of Drugs and Geography Forecast and Analysis 2021-2025

Marine Pharmaceuticals Market by Product and Geography Forecast and Analysis 2022-2026

Pregabalin Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 3.74%

Market growth 2022-2026

USD 153.03 million

Market structure

Fragmented

YoY growth (%)

3.27

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 36%

Key consumer countries

US, Canada, Germany, China, Japan, and Republic of Korea

Competitive landscape

Leading companies, competitive strategies, consumer engagement scope

Companies profiled

Biomax Biotechnics Pvt.Ltd., Camber Pharmaceuticals Inc., Cipla Ltd., Dr. Kumars Pharmaceuticals, Genesis Biotec Inc., H. L. Healthcare Pvt. Ltd., Lupin Ltd, Medley Pharmaceuticals Ltd., MK Medicine, MSN Laboratories, Neuracle Lifesciences Pvt. Ltd., Novartis AG, Pfizer Inc., Phoenix Biologicals Pvt. Ltd., Sun Pharmaceutical Industries Ltd, Swastik Life Sciences, Torrent Pharmaceuticals Ltd., and Vibcare Pharma Pvt. Ltd.

Market Dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents:

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Application

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

ContactTechnavio ResearchJesse MaidaMedia & Marketing ExecutiveUS: +1 844 364 1100UK: +44 203 893 3200Email:media@technavio.comWebsite:www.technavio.com/

Global Pregabalin Market 2022-2026

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/pregabalin-market-to-grow-by-usd-153-03-mn-from-2022-to-2026--driven-by-presence-of-large-patient-pool-related-to-neuropathic-pain---technavio-301640610.html

SOURCE Technavio

Read more:
Pregabalin Market to Grow by USD 153.03 Mn from 2022 to 2026, Driven by Presence of Large Patient Pool Related To Neuropathic Pain - Technavio - Yahoo...

This entry was posted on October 7, 2022 at 1:46 am and is filed under Neuropathy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |